CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
CANADA

About Us

Conference

Partner With Us

  • APAC
    • US
    • EUROPE
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    Bioinformatics & Genomics
    BioTech
    Cell and Gene Therapy
    Drug Discovery and Development
    Life Science AI
    Next-Generation Sequencing
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    CDMO
    Cosmetic
    CRO
    Life Science Testing And Compliance
    Supplement Manufacturing
  • Business Services
    Life Science Consulting
    Life Sciences Marketing and Communication
    Peptide
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Neurodegenerative Diseases
  • Top Neurodegenerative Diseases Companies in APAC

Neurodegenerative Diseases 2023

Top 10 Neurodegenerative Diseases Companies in APAC - 2023

Top 10 Neurodegenerative Diseases Companies in APAC - 2023

Neurodegenerative diseases like Alzheimer’s disease, Friedreich ataxia, Amyotrophic lateral sclerosis, and Parkinson's disease are at an all-time high, and so is the awareness about these diseases. This has propelled the market for neurodegenerative diseases and has given rise to a strong pipeline of treatments for such conditions.

According to research, the global neurodegenerative diseases market was valued at USD 40,125 million at the end of the last decade and is estimated to reach USD 53,275 million by 2030 at an astounding cumulative annual growth rate (CAGR) of 3.20 per cent. Out of this, the APAC market itself is predicted to be worth USD 13,530 million by 2030 recording a massive 5.03 per cent CAGR.

This Life Sciences Review issue highlights some of the most significant developments in the APAC market for neurodegenerative diseases and the considerable expansion of the sector in recent years. It features TauRx, founded to address one of the world's most pressing unmet medical needs - Alzheimer's disease and other neurodegenerative disorders - by targeting misfolding and aggregation of tau proteins. Its mission is to discover, develop, and commercialize novel products to diagnose, treat, and cure neurodegenerative diseases caused by protein aggregation.

The magazine also includes the insightful viewpoints of Steven Henck, PhD, Vice President of R&D, Integrated DNA Technologies, and Claus Feussner, Senior Vice President of Vetter Development Service, Vetter Pharma. They each address several valuable points related to treating Neurodegenerative diseases in the current technologydriven world.

Write to us about how the advancements in the APAC region's neurodegenerative diseases market have affected your organisation's functioning!

Top 10 Neurodegenerative Diseases Companies in APAC - 2023

Nominate a Company

Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.

* 

captcha
Can't read the image? click here to refresh

Thank You!

checkmark

We are glad to receive your nomination. Our editorial team and evaluation panel will review your submission. Thank you for taking the time to highlight an organization driving impactful change in Lifescience Review.

Data not inserted

    Top Neurodegenerative Diseases Companies in APAC

    ★Featured Companies
    TauRx
    TauRx
    Read full profile →
    TauRx was established to address one of the world’s greatest unmet medical needs - Alzheimer’s disease and other neurodegenerative disorders - by targeting the misfolding and aggregation of tau proteins. Its mission is to discover, develop, and commercialize innovative products for the diagnosis, treatment, and cure of neurodegenerative diseases caused by protein aggregation. ... read full profile
    AmplifyBio
    AmplifyBio
    Read full profile →
    AmplifyBio partners with clients to provide a single preclinical study or full IND enabling programs with a strategic focus on clients developing advanced therapies. The organization is still delivering excellence in the safety, efficacy, and toxicity testing from our world-class facility that previously was part of Battelle. ... read full profile
    ForestHills Lab
    ForestHills Lab
    Read full profile →
    Forest Hills Lab is an innovative regenerative medicine company seeking to improve the quality of life of our rapidly aging society and comprised of two divisions: Neuro-Med division is a therapeutic drug development platform focused on neurodegenerative diseases with high unmet need while Cos-Med division develops and markets a comprehensive line of aesthetics products globally. ... read full profile
    Oxford Immune Algorithmics (OIA)
    Oxford Immune Algorithmics (OIA)
    Read full profile →
    Through its flagship product, Algocyte, OIA is changing and moving medicine and healthcare away from a reliance on population-wide symptom pattern matching and toward precision medicine and personalised causal diagnostics. To achieve this, the company leverages responsible AI to monitor the immune system for early detection and treatment management. According to a survey of Algocyte’s solution independently conducted by a large NHS-affiliated clinic in the North of London, medical staff said that the use of Algocyte's immune score for triaging purposes could save up to two to three hours a week per junior doctor and nurse effectively increasing their capacity roughly by 5%. ... read full profile
Life Sciences Review APAC
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review APAC. All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://neurodegenerative-diseases-apac.lifesciencesreviewapac.com/vendors/top-neurodegenerative-diseases-companies-in-apac.html